Format

Send to:

Choose Destination
See comment in PubMed Commons below
PLoS Negl Trop Dis. 2009 Aug 25;3(8):e440. doi: 10.1371/journal.pntd.0000440.

Advancing drug innovation for neglected diseases-criteria for lead progression.

Author information

  • 1Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, Geneva, Switzerland.

Abstract

The current drug R&D pipeline for most neglected diseases remains weak, and unlikely to support registration of novel drug classes that meet desired target product profiles in the short term. This calls for sustained investment as well as greater emphasis in the risky upstream drug discovery. Access to technologies, resources, and strong management as well as clear compound progression criteria are factors in the successful implementation of any collaborative drug discovery effort. We discuss how some of these factors have impacted drug discovery for tropical diseases within the past four decades, and highlight new opportunities and challenges through the virtual North-South drug discovery network as well as the rationale for greater participation of institutions in developing countries in product innovation. A set of criteria designed to facilitate compound progression from screening hits to drug candidate selection is presented to guide ongoing efforts.

PMID:
19707561
[PubMed]
PMCID:
PMC2727960
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Public Library of Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk